SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant price drop, sparking a heated debate within the community where bears anticipate further decline driven by major liquidations and broader risk-off sentiment, contrasting with bulls who see this as a healthy shakeout and a prime accumulation opportunity.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amidst a sharp market sell-off, sparking heated community debate between those panicking over liquidations and macroeconomic concerns, and those viewing it as a prime 'buy the dip' opportunity before a key White House banking-crypto summit.

Elong Power Holding Ltd. engages in the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. The company was founded on August 18, 2023 and is headquartered in Ganzhou, China.

Elong Power Holding Ltd. - Ordinary Shares - Class A

Elong Power Holding Limited

ELPW is experiencing an explosive multi-thousand percent surge, sparking intense community discussion and FOMO. Traders are debating whether this low-float energy storage system company is undergoing a short squeeze, similar to other volatile small-cap Chinese listings, or if it's a pump-and-dump.

CLAWNCH

CLAWNCH is drawing significant attention as an "Alfa Ai Agent" crypto, with community discussion highlighting its recent notable performance and short-term trading opportunities.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger ($QRL) is trending as accelerating quantum computing breakthroughs and increasing warnings about "Q-Day" spark community discussion on its unique position as an early, quantum-resistant hedge against vulnerabilities in traditional cryptocurrencies. This sentiment is further fueled by upcoming QRL 2.0 functionality promising post-quantum smart contracts and increased accessibility through new exchange listings.

ProShares Trust - ProShares UltraPro Short Dow30 -3x Shares

ProShares UltraPro Short Dow30

SDOW is trending as the community positions aggressively for a significant market correction, leveraging this inverse Dow ETF amid rising geopolitical tensions and widespread skepticism regarding underlying economic health. Many traders are actively discussing the Dow's 'overvalued' state and anticipating a 'blood red' market, aiming to capitalize on an expected downturn despite common concerns about market manipulation and the structural decay inherent in leveraged bear funds.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending due to enthusiastic community-driven promotion centered around its 'What's UpDog?' meme, with supporters on the Solana network advocating for holding and buying dips to solidify its position as a retail-driven asset.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care is trending amid community discussions highlighting its successful adoption of DefenCath, a solution significantly reducing life-threatening bloodstream infections in dialysis patients. This strategic move positions FMS as a leader in patient safety and a key component of its 'FME Reignite' strategy for growth in the renal care sector.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Trust

Grayscale Ethereum Trust is in focus following the SEC's approval of spot Ethereum ETFs, driving community discussions around its high management fees and significant outflows as investors consider rotating into new, lower-cost alternatives, despite continued bullish long-term sentiment for Ethereum.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending amidst general crypto market turbulence, notably showing institutional inflows and robust on-chain activity even as other major tokens see outflows. The community actively debates 'buy the dip' opportunities, though discussions also highlight concerns regarding a lawsuit impacting its ecosystem and the prevalence of meme coins.

statis crypto Watchlist

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fifteen research firms that are currently covering the stock...

Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Should You Sell?

Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Here's Why...

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor...

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.

Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading Volume - Here's Why

Janux Therapeutics (NASDAQ:JANX) Sees Unusually-High Trading Volume - Still a Buy...

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.read more...

<ul class="summary-bullets"><li>Under the agreement, Janux will manage preclinical development through IND submission.</li><li>Bristol Myers Squibb will hold the IND, oversee subsequent clinical development, and lead global commercialization efforts.</li><li>The deal provides Janux with up to $50 million in upfront and near-term milestone payments.</li></ul>Janux Therapeutics, Inc. (JANX) announced on Thursday that it has entered a strategic collaboration with Bristol Myers Squibb to advance the development of a new tumor-activated therapy.&nbsp;The partnership focuses on a yet-to-be-disclosed solid tumor target expressed across multiple cancer types, aiming to expand treatment options for patients worldwide.<h2 class="st-heading-2">Collaboration Details</h2>Under the agreement, Janux will manage preclinical development through IND submission, whileBristol Myers Squibb will hold the IND, oversee subsequent clinical development, and lead global commercialization efforts.&nbsp;The collaboration ensures Janux remains actively engaged, supporting the completion of the first Phase 1 clinical study alongside Bristol Myers Squibb.<blockquote>“This collaboration marks a significant milestone for Janux, validating the strength of our tumor-activated platforms and expanding our reach in solid tumor oncology.”&nbsp;- David Campbell, President and CEO, Janux</blockquote>Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/JANX">Janux Therapeutics’ stock</a> traded over 8% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Financial Terms</h2>The deal provides Janux with up to $50 million in upfront and near-term milestone payments. Additional development, regulatory, and commercial milestones could total roughly $800 million. Additionally, Janux will receive tiered royalties on worldwide product sales, giving the company potential long-term revenue streams if the therapy succeeds.This tie-up will use Janux’s proprietary technologies, including its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. These platforms are designed to enhance the immune system targeting of tumors while minimizing off-target effects.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/netflix-warner-bros-deal-paramount-seeks-wbd-shareholder-suppot/cmUzzULR4QC">Netflix-Warner Bros. Deal: Paramount Seeks WBD Shareholder Support To Counter Amended NFLX Transaction, Extends Tender Offer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A staff member of the Baden-Württemberg State Health Authority is pipetting corona samples during an experiment.

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb

The company, along with Bristol Myers Squibb, will develop a new tumor-activated therapy.

Equity

The company, along with Bristol Myers Squibb, will develop a new tumor-activated therapy.


Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor...

Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold

Clear Str cut shares of Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday...

Janux Therapeutics (NASDAQ:JANX) Reaches New 1-Year Low - What's Next?

Janux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low - Here's Why...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest JANX News

JANXJanux Therapeutics Inc